. 2018 Nov 14;8:16791. doi: 10.1038/s41598-018-35014-1

Table 3.

The changes of intestinal microflora in participates after L. reuteri consumption.

Microbial groups	Placebo (N = 21)^a,c	ADR-1 (N = 22)^a	ADR-3 (N = 24)^a	P-value^b
Microbial groups	Placebo (N = 21)^a,c	ADR-1 (N = 22)^a	ADR-3 (N = 24)^a	placebo vs. ADR-1	placebo vs. ADR-3	ADR-1 vs. ADR-3
Lactobacillus_reuteri	1.53 ± 1.77	98.43 ± 174.3	6.23 ± 11.25	0.017	0.055	0.022
Lactobacillus spp.	2.51 ± 3.66	5.47 ± 20.02	14.53 ± 52.73	0.503	0.277	0.44
Bifidobacterium spp.	6.28 ± 19.74	3441 ± 15649	73.72 ± 156.2	0.315	0.049	0.324
Akkemansia muciniphila	25.84 ± 59.38	81.07 ± 268.2	170 ± 818.3	0.356	0.398	0.618
Clostridium cluster I	20.43 ± 81.26	2.21 ± 2.78	5.57 ± 10.21	0.317	0.415	0.132
Bacteroidetes	1.42 ± 1.29	7.21 ± 24.39	2.47 ± 3.53	0.28	0.18	0.38
Firmicutes	1.57 ± 2.71	1.62 ± 1.73	3.02 ± 3.35	0.94	0.12	0.08
Bacteroidetes/Firmicutes	−99.37 ± 338.03	22.28 ± 166.75	−87.98 ± 213.26	0.15	0.9	0.06

^aFecal microflora was analyzed by quantitative PCR as described in “Materials and Methods” section and presented as fold change at 6 month when compared with starting point (mean ± SD).

^bTwo sample t-test analysis was used to compare mean values between groups as indicated.

^cOne participate in placebo group lost stool sample.